Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the blood-brain barrier making it an attractive candidate not only for MS but for the treatment of other neurological disease.
| less than a minute read
Sanofi Enters the Race to Develop a New Drug for Multiple Sclerosis
Get in touch
Get in touch
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma. The French Big Pharma is paying $40 million upfront to pick up the preclinical asset, with $765 million more to follow if it passes all the milestones that await.
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-06-07-08-32-37-760-6662c5a5e17f2f97387a4d96.png)
Welcome to the first edition of the Life Sciences Index, a study about perceptions of innovation and growth in the life sciences...
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-07-25-10-18-27-122-66a22673360ba83a1870b4e7.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-07-22-08-59-02-553-669e1f560e665f7cf84d24e4.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-07-09-15-46-56-542-A24006_Life_Sciences_June_2024_Brochure_ENv2_thumbnail_1.png)
